Contractor appointed to multi-million Reckitt Benckiser pharmaceutical centre

A MAJOR pharmaceutical research and innovation facility being built in Hull has taken a step forward with the appointment of contractor Balfour Beatty Kilpatrick.

Balfour’s mechanical and electrical arm has been awarded a £20m contract by engineering firm M+W Group for Reckitt Benckiser.

RB, which owns the Dettol and Nurofen brands, is looking to develop the “state of the art” facility after announcing a £100m investment in Hull two years ago.

It said the site will be operational by early 2018, securing 1,200 jobs. It will be involved in developing Strepsils and Nurofen.

Works by Balfour are commencing this month and will include the installation of a new ventilation system, small power and lighting systems, fire and intruder alarms and a building management system.

The company will employ 175 on the job.

Simon Lafferty, Balfour Beatty Kilpatrick managing director said: “This facility will be a flagship building and will allow us to showcase our wide range of mechanical and electrical expertise, including our design team’s knowledge of hi-tech and process sectors.

“We have collaborated with M+W Group to produce a joint BIM strategy, as well as detailed programme and commissioning plans to facilitate their needs both in the construction phase and beyond.”

Close